Valeo Pharma Inc.
VPHIF · OTC
7/31/2024 | 4/30/2024 | 1/31/2024 | 10/31/2023 | |
|---|---|---|---|---|
| Market Cap | $5 | $5 | $29 | $14 |
| - Cash | $7 | $7 | $10 | $8 |
| + Debt | $70 | $68 | $66 | $65 |
| Enterprise Value | $68 | $66 | $85 | $71 |
| Revenue | $13 | $14 | $14 | $13 |
| % Growth | -10.8% | 4.4% | 3.3% | – |
| Gross Profit | $3 | $3 | $2 | $1 |
| % Margin | 27.3% | 19.4% | 15.5% | 4.8% |
| EBITDA | -$4 | -$3 | -$4 | -$5 |
| % Margin | -29.2% | -23.6% | -31.8% | -37.1% |
| Net Income | -$8 | -$8 | -$7 | -$9 |
| % Margin | -65% | -55.3% | -50.8% | -70.5% |
| EPS Diluted | -0.083 | -0.079 | -0.08 | -0.098 |
| % Growth | -4.8% | 0.8% | 18.8% | – |
| Operating Cash Flow | $0 | -$4 | $1 | -$3 |
| Capital Expenditures | $0 | -$0 | -$0 | -$5 |
| Free Cash Flow | $0 | -$4 | $1 | -$8 |